The PI3K pathway as drug target in human cancer - Test2 - elhamkhani - TriplyDB

The PI3K pathway as drug target in human cancer

The PI3K pathway as drug target in human cancer

http://www.wikidata.org/entity/Q24632283

about

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer Markers of resistance to anti-EGFR therapy in colorectal cancer Analysis of the genome to personalize therapy for melanoma Retroviral oncogenes: a historical primer mTOR inhibitors in advanced renal cell carcinoma Pushing the envelope in the mTOR pathway: the second generation of inhibitors Advances in targeted and immunobased therapies for colorectal cancer in the genomic era Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma PI3K/Akt/mTOR inhibitors in breast cancer Targeted therapy for advanced gastric cancer: A review of current status and future prospects Lipid metabolic reprogramming in cancer cells PI3K and AKT: Unfaithful Partners in Cancer What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment Targeting Apoptosis and Multiple Signaling Pathways with Icariside II in Cancer Cells Metabolism and breast cancer risk: frontiers in research and practice Growth factor and signaling pathways and their relevance to prostate cancer therapeutics Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis Ten things you should know about protein kinases: IUPHAR Review 14 Emerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorder Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer.Investigating the structure and dynamics of the PIK3CA wild-type and H1047R oncogenic mutant CIViC database Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma The PTEN Long N-tail is intrinsically disordered: increased viability for PTEN therapy Suppression of survival signalling pathways by the phosphatase PHLPP

P2860

1d2336539973b6ebb27d0385fc473e8561a5a370

P248

Q24338724-29AE217F-1405-4779-9ED5-EFC55711D635 Q24598640-6481CD3D-1638-4FEE-9017-249A3D8B6FC6 Q24601008-097B511A-43B2-4483-AD6B-80E1341C35B4 Q24611142-FC70A7AC-2D08-4D9A-B338-129D63987F01 Q24612127-B341BEDE-D54C-435D-A83A-4ADC6914B37C Q24622222-B10573F4-9357-4C61-BB76-44700988AF1D Q26751344-862FDA50-BAA6-486C-987B-13DE2CEC1CBE Q26766292-3CF3B352-78DA-4700-9583-73C51B58ABA1 Q26766293-44C9452C-BEE2-490E-9C26-BB6D4E2961CC Q26771394-06DCC04F-C4C7-447E-8B28-3CE249AD4F82 Q26774138-254D7006-6E4B-48EC-ACDF-36C49E4EC604 Q26774859-9AF47AB6-8403-434E-96DA-3D80009AB9D5 Q26781367-2BE9C3BF-39AB-44A3-99AA-A207B5CDC870 Q26782585-6D39EEEB-3E0F-46C2-8AED-9CD930180B97 Q26798203-5AF61743-9879-4492-9F50-6D156480BB85 Q26823745-51FEBB3C-68DC-43CE-9DDA-F9B1C47A9495 Q26827975-2445BFAF-8412-48CC-ABE1-DFC2A39A6FF2 Q26829652-CA26F93F-C279-471F-BA49-005498946180 Q26830671-FC5DFCDA-32FC-4931-8CAF-3634573A2CF3 Q26849417-B0A6C0B4-6473-4AFE-B3EB-8BF289763827 Q26859114-626D2CD9-1451-48D8-AEB8-2E54C76BABFD Q26865645-687AFFDB-4689-484B-BC8F-9584779F1C3A Q27006181-3309FE32-E409-4113-AB00-09318FFBF306 Q27009016-D4C9393C-CB3C-43A9-9337-81DB5F035309 Q27015224-AF8AAC1E-C413-404E-9297-A511745FE7C6 Q27025970-2BDFA5EA-A853-463C-B37C-86CEBB49AE71 Q27308683-EED3D570-1850-4D74-9FA7-DC105FD0DB8D Q27320874-ED1097DB-7D51-459A-9D89-1FC8DC2C2DC3 Q27612411-27746C9C-1B3A-4DBA-B925-C562EAA3A39A Q27684163-BF647E12-FCE6-467B-B5D2-9598EF494414 Q27853088-C6619CF6-DD26-48DA-AC47-4390984BA2BC Q27853128-750D5FAE-79E2-4B9B-B003-A2DFD5B131BE Q27853324-B82F1562-6CE3-42C8-82B0-C84B68646735 Q28067417-3E31B46A-6637-48E9-ABEB-244EFA852841 Q28076622-85C4053E-A22E-47BB-B36F-492AFFA3E10B Q28079596-CCCABC2C-0FE7-4C58-A0A8-BF2AE69247E6 Q28079848-13CBCD4C-FA4A-463B-9CF5-ECE2FD04DA2A Q28115966-F5340F45-46AB-4616-A864-43A22B21AF8D Q28299026-03CC1D9C-37E3-46AF-8C53-94009D48EEF1 Q28388451-0558761A-B6B0-41D4-B47B-69B865A9A302

P2860

The PI3K pathway as drug target in human cancer

http://www.wikidata.org/entity/Q24632283

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

The PI3K pathway as drug target in human cancer

@ast

The PI3K pathway as drug target in human cancer

@en

The PI3K pathway as drug target in human cancer

@nl

type

label

The PI3K pathway as drug target in human cancer

@ast

The PI3K pathway as drug target in human cancer

@en

The PI3K pathway as drug target in human cancer

@nl

altLabel

The PI3K Pathway As Drug Target in Human Cancer

@en

prefLabel

The PI3K pathway as drug target in human cancer

@ast

The PI3K pathway as drug target in human cancer

@en

The PI3K pathway as drug target in human cancer

@nl

P1433

Q24632283-40C27A0F-CCEF-45F8-BD07-261DBFE79A2A

P1476

Q24632283-AC0DF32D-9EAD-4E4B-BA24-49A7E98139EA

P2093

Q24632283-3CC04DF3-BA37-47FF-988C-F01592CE6719

Q24632283-43BFF3B7-256A-42DE-B991-3DB56388B3D4

Q24632283-E10A1426-3593-42A5-915E-0D925BDB4DF5

P2860

Q24632283-018542CD-98B7-45C7-B096-8730ECF4C5D2

Q24632283-05A27516-0696-427A-9F5E-4B93BACAA35F

Q24632283-09F52E97-49E1-4C60-AA57-BC9176F87493

Q24632283-0A941C39-5AC6-43F9-A4D8-CFD96E27D408

Q24632283-0CFBFF06-42B5-45F8-8E4C-98F97BBA7110

Q24632283-0EC5F0A8-496A-401B-A327-46376AF3C152

Q24632283-13C25015-97DA-42BC-8628-37BD89450742

Q24632283-1771AB71-E0FF-4CAA-967D-D8BD343DDB10

Q24632283-188EE47A-BAAB-4033-8AA4-C2AFA3E306B6

Q24632283-18D5C39F-EBB6-44C4-AC30-36C7C44933D5

P304

Q24632283-821C2FC2-85B3-4022-8B61-7E76207A765F

P31

Q24632283-B34D8DA6-3C18-4C9A-9DFB-BE1377B6589A

P3181

Q24632283-CFAD2F58-4BE9-43FA-80B7-E26C51122999

P356

Q24632283-C4142CF5-F769-4DBE-A900-3A8B83CCF46B

P407

Q24632283-CCE83EB1-B241-4ECC-99EF-6AD1BAA9753C

P433

Q24632283-E20B918F-A876-4FB7-AF18-4E9ACE192A3F

P478

Q24632283-852A21C5-FBD2-470D-A21E-5243C890A131

P577

Q24632283-552C1D53-0C90-4790-8C57-D8C08A299CC2

P5875

Q24632283-2BFDF021-448B-4DBE-B642-1A21553D5DB6

P698

Q24632283-1B23563C-6E2F-4946-AC1F-23D81CAD9B36

P932

Q24632283-624CEF86-D79A-4026-BD3F-2892FF6C5C21

P3181

P356

JCO.2009.25.3641

P1433

Journal of Clinical Oncology

P1476

The PI3K pathway as drug target in human cancer.

@en

P2093

Jeffrey A Engelman

http://www.w3.org/2001/XMLSchema#string

Kevin D Courtney

http://www.w3.org/2001/XMLSchema#string

Ryan B Corcoran

http://www.w3.org/2001/XMLSchema#string

P2860

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

The lipid phosphatase activity of PTEN is critical for its tumor supressor function

AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice

Should individual PI3 kinase isoforms be targeted in cancer?

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase

Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1

Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA

P304

1075-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

339283

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2009.25.3641

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41088040

http://www.w3.org/2001/XMLSchema#string

P698

20085938

http://www.w3.org/2001/XMLSchema#string

P932

2834432

http://www.w3.org/2001/XMLSchema#string